Single-inhaler triple therapy reduces COPD exacerbations vs dual therapies in ETHOS trial
The phase III ETHOS trial compared the efficacy and safety of two dose levels of single-inhaler, fixed-dose, triple combinations of budesonide/glycopyrrolate/formoterol fumarate (BGF) with dual combinations of glycopyrrolate/formoterol fumarate (GF) and budesonide/formoterol fumarate (BF) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). At the American Thoracic Society 2020 virtual session on clinical trials held recently, lead investigator Professor Klaus Rabe of the University of Kiel, Germany, presented the findings demonstrating superiority of the triple combination regimens over the two dual therapies.

New Molecule

4 New

New Formulation

2 New

New Indication

5 New

Color 1
Color 2